undamentalytics Newsletter
Sign in

Tenax Therapeutics, Inc. income statement

In fiscal 2025, Tenax Therapeutics, Inc. reported revenue of $0 and net income of −$52.6m, or −$1.34 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Apr 20112012Apr 20122013Apr 20132014Apr 20142015Apr 20152016Dec 20162024Dec 20242025Dec 2025LTMJun 2026
Revenue001000000
Gross profit000−000———
Research and development3223713133345
Selling, general and administrative8641476———
General and administrative——————724—
Operating income11−8−5−17−15−53−19−56−69
Interest expense−07420000—
Income tax———00−800—
Net income10−16−9−20−14−44−18−53−65
Diluted EPS−$96000.00−$150080.00−$71253.33−$28906.67−$16000.00−$49984.00−$1.15−$1.34−$1.47
Diluted shares (average)109m130m165m———15m39m44m
EBITDA11−8−5−16−15−53−19——

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Health Care sector, rankings of US companies

Figures from Tenax Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tenax Therapeutics, Inc.